Important New EU MDR Guidance on “Significant Change” and Clinical Evidence for Software

The EU Medical Devices Regulation will apply in little more than two months, under highly unusual circumstances. The COVID-19 global health crisis is now putting additional strain on the already overburdened medtech industry, and tensions around the revision of the Swiss-EU mutual recognition agreement are adding to the pressure. However, some positive news for the industry is the Medical Device Coordination Group’s (MDCG) release of much-needed guidance on a number of key topics that will assist industry in its efforts to comply with the MDR, as well as the EU In Vitro Diagnostic Medical Devices Regulation IVDR.

1. Guidance to determine what is a “significant change” in design and intended purpose of medical devices

As reported in our last Sidley MDR Update (click here), the interpretation of what constitutes a “significant change” is key for devices that benefit from the transitional provisions set out in Article 120(3) of the MDR. This is because devices with valid CE certificates issued under the EU Medical Devices Directive (MDD) or the EU Active Implantable Medical Devices Directive (AIMDD) prior to May 26, 2020, will no longer benefit from these transitional provisions if they undergo a “significant change.”

This week, the MDCG published guidance on what constitutes a “significant change” under Article 120(3) of the MDR with regard to devices covered by certificates issued under the MDD or AIMDD.

Flowcharts are included and are largely based on the Notified Body Operations Group’s previous guidance (available here). These flowcharts provide a roadmap of different assessment steps, which can be taken to reach the result and according to which a change should be deemed “significant” or not. A separate flowchart is provided for each of the following changes:

• changes in intended purpose, noting that changes other than a limitation of the intended purpose will nearly always be considered “significant”
• changes in the design or performance of the specification, noting that certain changes in the design related to corrective actions may be deemed not “significant”
• software changes, as further detailed below
• changes of a material
• changes of terminal sterilization method of the device or changes to the packaging design affecting the sterilization

Software changes that will generally not be considered “significant” include, inter alia, correction of an error that does not pose a safety risk (e.g., bug fixes), security updates (e.g., cybersecurity enhancements), appearance of the user interface, operating efficiencies, and enhancement of the user interface without influencing the performance.

The guidance reminds manufacturers that they must bring any change in the design or intended purpose of their medical devices to the attention of their notified body, which will assess whether such change is “significant” on a case-by-case basis. The guidance opens up the opportunity for notified bodies to confirm in writing that a change does not qualify as “significant” for the purposes of Article 120(3) of the MDR.

2. What and how much clinical evidence do manufacturers of medical devices need to justify conformity of MDSW?

This guidance is still subject to revision but provides important guidance for medtech companies trying to collect clinical evidence for their medical device software (MDSW).

The following principles aim to guide industry in the generation of such evidence:

• Manufacturers must verify that the information generated by the MDSW relates to the targeted condition indicated in the relevant device’s intended purpose. This can be done, for example, on the basis of literature searches, professional guidelines, proof of concept studies or the manufacturer’s own studies
• Manufacturers must also verify that the MDSW reliably, accurately and consistently meets the intended purpose in real-world usage. This can be demonstrated through validation and verification studies, for instance, unit-level, integration and system testing, or by generating new evidence through the use of curated databases, curated registries, reference databases or previously collected patient data
• Manufacturers must demonstrate that the MDSW has been tested for the intended use, target population, use conditions, operating and use environments, and with all intended user groups

The guidance also provides useful indications on the level of clinical evidence that notified bodies will expect (quantitatively and qualitatively) from manufacturers of MDSW. An annex contains practical examples of evaluation strategies for specific MDSW.

3. How can manufacturers of some Class I medical devices make efficient use of the transitional provisions in Article 120(3) and (4) of the MDR?

 As reported in Sidley’s Updates (see here), last December the EU legislator adopted, in a second corrigendum to the MDR, a four-year transition period for certain low-risk medical devices.

The guidance clarifies the conditions that manufacturers must fulfil in order to continue to place Class I medical devices certified under the current regime on the EU market until May 26, 2024. The guidance also provides clarifications of the information that manufacturers of such devices must provide in a valid Declaration of Conformity.

Along with the documents outlined above, this week the MDGC also issued this week (i) guidance on Unique Device Identification and (ii) guidance on implant cards to be provided to patients pursuant to Article 18 of the MDR.